Aspira Womens Health (FRA:CUL) Net Cash per Share : €-0.38 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Aspira Womens Health Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Aspira Womens Health's Net Cash per Share for the quarter that ended in Mar. 2024 was €-0.38.

The historical rank and industry rank for Aspira Womens Health's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Aspira Womens Health was 103.76. The lowest was 4.46. And the median was 9.49.

FRA:CUL's Price-to-Net-Cash is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 6.785
* Ranked among companies with meaningful Price-to-Net-Cash only.

Aspira Womens Health Net Cash per Share Historical Data

The historical data trend for Aspira Womens Health's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Net Cash per Share Chart

Aspira Womens Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

Get a 7-Day Free Trial

0.92

0.80

3.11

0.33

-0.52

Aspira Womens Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Cash per Share	Get a 7-Day Free Trial															-0.35	-0.44	-0.38	-0.52	-0.38

Competitive Comparison of Aspira Womens Health's Net Cash per Share

For the Diagnostics & Research subindustry, Aspira Womens Health's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Price-to-Net-Cash falls into.

Aspira Womens Health Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Aspira Womens Health's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.381	-	7.911	-	0)	/	10.6451
=	-0.52

Aspira Womens Health's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

	Net Cash per Share (Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(3.14	-	7.845	-	0)	/	12.3441
=	-0.38

Aspira Womens Health (FRA:CUL) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Aspira Womens Health Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (FRA:CUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » Net Cash per Share

Comparable Companies

DRIO OCX ENZ BIAF PRE TTOO XGN DMTK SLDX MYNZ TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

AWH:USA

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines